You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窩輪》【瑞通認股證牛熊證】美團涉壟斷被查 股價先跌後升 較多資金即市開熊 恆指牛68708 熊67601/ 美團牛51334 熊59322 購16108 沽16119
阿思達克 04-27 10:38
市場觀望多隻科技股周內公佈的季績,美股隔晚個別發展。道指收報33981點,跌61點(或0.2%);納指則升0.9%,創收市新高。恆指昨尾市沽壓加劇,收報28952點,跌125點(或0.43%)。今早曾再跌逾100點,一度跌破28800點,其後回穩。 恆指好倉(牛證及認購權證)昨淨流入逾5100萬港元(下同),恆指淡倉(熊證及認沽權證)同日淨流出逾230萬元,反映投資者看好大市反彈。昨日恆指牛證街貨重貨區為收回價28500至28599點,而熊證街貨重貨區為收回價29800至29899點。

國家市場監管總局表示,根據舉報依法對美團(03690)實施「二選一」等涉嫌壟斷行為立案調查。美團回應將積極配合監管部門調查,嚴格落實相關規定,目前公司業務一切正常。有券商預料美團面對的行政處罰區間介乎40億至120億元人民幣。美團是昨日成交最活躍股份,股價最多升近半成至321元以上,惟午後走勢逆轉,倒跌0.5%收市,報305元。今早跌逾2%,曾低見296.4元,考驗10及20天線的支持(分別約294和298元),惟其後迅速倒升,不止收復300元關口,更一度升至312元之上的水平。昨有逾7億元北水淨買入美團。輪證資金流方面,各有超過1900萬元淨流入其好倉和淡倉,分別為個股好淡倉項目中資金淨流入的頭兩位。

藥明生物(02269)大股東以每股107元配售1.08億股現有股份,套現逾115億元,是繼一月和二月後今年第三次進行配股。該股昨升上兩個月高位後回落,倒跌0.2%收114.8元,今早挫6%,一度回落至108元之下,正考驗10天線(109元) 支持。昨有逾300萬元淨流出其好倉,淡倉同日則有逾30萬元淨流入。

匯控(00005)今公佈首季度業績,券商預測集團期內列帳基準除稅前利潤介乎26.49億至36.93億美元,按年下跌18%至上升14.4%。市場關注匯控按季淨息差表現及重組步伐。股份昨窄幅上落,收報45.1元,微升0.7%結束三連跌。今早靠穩,於45元以上徘徊。昨有逾330萬元淨流入其好倉,淡倉同日則有逾50萬元淨流出。

據報美國政府擬要求煙草公司將所有在美國出售的香煙尼古丁含量降至不成癮水平,或驅使部份煙民轉投電子煙。生產電子煙霧化組件的思摩爾(06969),上日曾急漲7.4%至58.7元,創一個月高,收市維持4.1%升幅於56.9元,或已消化季績後的沽壓。股份今早先升後回,上試58元水平見阻力,其後轉跌1%。昨有逾430萬元淨流入其好倉,淡倉同日資金流變化不大。

瑞通相關認股證之選擇:

美團輕微價外、中短期購16108,行使價:345元,2021年9月到期,實際槓桿:5.4倍

美團輕微價外、中短期沽16119,行使價:269.8元,2021年8月到期,實際槓桿:5.3倍

藥明輕微價外、中短期購26864,行使價:126.88元,2021年8月到期,實際槓桿:4.8倍

匯豐輕微價外、中短期購15127,行使價:48.88元,2021年8月到期,實際槓桿:10.4倍

匯豐貼價、中短期沽15035,行使價:43.88元,2021年8月到期,實際槓桿:7.4倍

思摩輕微價外、中年期購16109,行使價:60.969元,2021年11月到期,實際槓桿:2.2倍

騰訊輕微價外、中短期購11712,行使價:729.38元,2021年10月到期,實際槓桿:7.1倍

騰訊輕微價外、中短期沽20807,行使價:555.38元,2021年8月到期,實際槓桿:8.1倍

瑞通相關牛熊證之選擇:

恆指牛證68708,收回價:28500點,槓桿比率:45倍

恆指熊證67601,收回價:29390點,槓桿比率:50倍

美團牛證51334,收回價:280.2元,槓桿比率:12.6倍

美團熊證59322,收回價:346.88元,槓桿比率:5.4倍

全場最貼藥明牛證66183,收回價:101.88元,槓桿比率:9.5倍

藥明熊證56714,收回價:118.8元,槓桿比率:7.6倍

匯豐牛證64079,收回價:43元,槓桿比率:12.6倍

匯豐熊證59349,收回價:48.88元,槓桿比率:8.7倍

思摩牛證50724,收回價:53.08元,槓桿比率:6.7倍

騰訊牛證59297,收回價:591元,槓桿比率:17倍

騰訊熊證59309,收回價:658.88元,槓桿比率:13.5倍

重要風險通知

本結構性產品並無抵押品。

結構性產品之價格一般可急升亦可急跌,有可能損失結構性產品之全部或重大部分購買價,閣下對此應有所準備。

閣下投資前應了解產品風險,如有需要應諮詢專業建議。~

重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account